BidaskClub Lowers Meridian Bioscience (VIVO) to Sell
Meridian Bioscience (NASDAQ:VIVO) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Saturday.
A number of other analysts have also commented on the company. Canaccord Genuity reiterated a “hold” rating and set a $14.00 price target on shares of Meridian Bioscience in a report on Friday, October 13th. Zacks Investment Research lowered Meridian Bioscience from a “hold” rating to a “sell” rating in a report on Tuesday, October 24th.
Meridian Bioscience (VIVO) opened at $15.20 on Friday. The stock has a market capitalization of $643.07, a P/E ratio of 29.80 and a beta of 0.98. The company has a current ratio of 5.85, a quick ratio of 4.04 and a debt-to-equity ratio of 0.30. Meridian Bioscience has a 1 year low of $12.15 and a 1 year high of $16.45.
A number of institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in Meridian Bioscience by 9.1% during the second quarter. Vanguard Group Inc. now owns 4,018,985 shares of the company’s stock worth $63,299,000 after acquiring an additional 334,480 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Meridian Bioscience by 4.8% during the third quarter. Dimensional Fund Advisors LP now owns 1,748,848 shares of the company’s stock worth $25,008,000 after acquiring an additional 80,877 shares during the period. Bank of New York Mellon Corp lifted its holdings in Meridian Bioscience by 1.0% during the third quarter. Bank of New York Mellon Corp now owns 871,560 shares of the company’s stock worth $12,463,000 after acquiring an additional 8,377 shares during the period. Northern Trust Corp lifted its holdings in Meridian Bioscience by 1.6% during the second quarter. Northern Trust Corp now owns 557,398 shares of the company’s stock worth $8,780,000 after acquiring an additional 8,886 shares during the period. Finally, Schwab Charles Investment Management Inc. lifted its holdings in Meridian Bioscience by 12.4% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 471,456 shares of the company’s stock worth $6,601,000 after acquiring an additional 51,976 shares during the period. Institutional investors and hedge funds own 86.87% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “BidaskClub Lowers Meridian Bioscience (VIVO) to Sell” was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.watchlistnews.com/bidaskclub-lowers-meridian-bioscience-vivo-to-sell/1840782.html.
Meridian Bioscience Company Profile
Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.
Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.